title: Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
abstract: In order to evaluate in a double-blind manner the therapeutic efficacy of selegiline in the treatment of late-phase Parkinson's disease, 19 patients with end-of-dose type fluctuations were randomized for a double-blind cross-over trial receiving either selegiline 10 mg or placebo. Each period lasted 12 weeks. During a two week prestudy period the dose of levodopa was titrated to optimal levels. The disability was evaluated using the Columbia University Disability Scale (CUDS). The patients kept a daily diary to monitor closely the frequency and severity of their fluctuations and the side-effects of treatment. Their parkinsonian disability and all main symptoms improved significantly during selegiline treatment. The mean duration of action of a levodopa dose was significantly longer and there was significantly less daily end-of-dose and early morning akinesia during selegiline treatment. The side-effects were similar in both treatments. This double-blind study confirms the findings of earlier open studies that selegiline potentiates and prolongs the therapeutic effects of levodopa and thus its use is particularly beneficial in patients with end-of-dose type fluctuations in disability.
authors.affiliation: Department of Neurology, University of Turku, Finland.
authors.forename: E H
authors.initials: EH
authors.lastname: Heinonen
authors.forename: U K
authors.initials: UK
authors.lastname: Rinne
authors.forename: J
authors.initials: J
authors.lastname: Tuominen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
chemical_list: D010627:Phenethylamines; D012642:Selegiline; D007980:Levodopa